Shopping Cart

Expired activity

Please go to the PowerPak homepage and select a course.

TARGET AUDIENCE

This activity is intended for health care decision makers (HCDMs) including pharmacists from MCOs, ACOs, IDNs, specialty pharmacy providers, and other health systems.

GOAL

Diabetes mellitus is a chronic progressive disease affecting an estimated 30 million Americans—nearly one in every ten persons—and its prevalence continues to increase with 1.4 million Americans newly diagnosed each year. Patients with type 2 diabetes mellitus (T2DM) represent 90%-95% of cases. Diabetes is associated with elevated risk for complications such as kidney failure, blindness, and lower limb amputations, comorbidities including hypertension and dyslipidemia, and increased cardiovascular mortality all of which lead to increased medical costs and indirect costs from work-related absenteeism, reduced productivity, and premature mortality. This activity highlights opportunities for health care decision makers (HCDMs) to improve the management of T2DM for their health plan members by implementing and/or recommending evidence-based practice recommendations within the framework of published treatment guidelines and patient-centered care.

Educational Objectives

After completing this activity, the participant should be better able to:

• Assess emerging and recently approved insulin-based combination therapies for the treatment of T2DM and cite their clinical trial data
• Apply strategies to increase coordination of diabetes care among multidisciplinary teams within the managed care setting
• Review a patient-centered approach for T2DM management and improved adherence to treatment
• Recommend a benefit design strategy that payers can implement to improve clinical outcomes and the overall value of T2DM management

Faculty

	Vanita R. Aroda, MD Scientific Director, Physician Investigator MedStar Community Clinical Research Center Associate Professor of Medicine, Endocrinology, Diabetes, and Metabolism Georgetown University School of Medicine		Jeffrey Dunn, PharmD, MBA Senior Vice President Chief Clinical Officer VRx/MagellanRx
	Edmund Pezalla, MD, MPH CEO Enlightenment Bioconsulting

DISCLOSURE OF CONFLICTS OF INTEREST

It is the policy of Medical Education Resources, Inc. (MER) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

ACCREDITATION

Continuing Pharmacy Education
Medical Education Resources, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Medical Education Resources, Inc. designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number — 0816-9999-17-080-H01-P)

Type of Activity: Knowledge

Published: March 1, 2017
Expires: September 30, 2018

Media: Internet

Fee Information: There is no fee for this educational activity.
Estimated Time to Complete Activity: 0.5 hours

HOW TO EARN CREDIT

During the period March 1, 2017 through September 1, 2018, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Submit Posttest at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your Statement of Participation will be made available immediately. Click on the View Statement of Participation and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

If you have any questions relating to the certification of this activity, please contact Medical Education Resources, Inc. via www.mer.org.

Disclosure of Unlabeled Use and Disclaimer

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.